Scientists conducted a clinical trial in 14 patients with newly diagnosed, human papillomavirus-unrelated head and neck squamous cell carcinoma to evaluate the safety and efficacy of neoadjuvant bintrafusp alfa, a bifunctional fusion protein that blocked programmed death-ligand 1 (PD-L1) and neutralized transforming growth factor-beta (TGF-b).
[Journal of Clinical Investigation]